PEGylation of an osteoclast inhibitory peptide: Suitable candidate for the treatment of osteoporosis

International Journal of Pharmaceutics

Volumn 434, Issue 1-2, 2012, Pages 429-436

  Akhtar, Jabed ^a   Mallaredy, Vandana ^b   Dandapat, Jagneshwar ^c   Maiti, Prasanta ^a   Sahoo, Sanjeeb K ^b   Singh, Sujay ^a  

^a Imgenex India Pvt Ltd   (India)

^b INSTITUTE OF LIFE SCIENCES   (India)

^c UTKAL UNIVERSITY   (India)

Author keywords

Bioavailability; PEGylated peptide; RANK; TRAF 6 Inhibitory peptide

Indexed keywords

PEGYLATED TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 INHIBITORY PEPTIDE; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SYNTHESIS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BIOLOGICAL AVAILABILITY; BONE MARROW; DRUG DELIVERY SYSTEMS; FEMALE; HALF-LIFE; MICE; MICE, INBRED C57BL; OSTEOCLASTS; OSTEOPOROSIS; PEPTIDES; POLYETHYLENE GLYCOLS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; TNF RECEPTOR-ASSOCIATED FACTOR 6;

EID: 84864127212     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.06.012     Document Type: Article

References (30)

1. JAMA Osteoporosis prevention, diagnosis, and therapy JAMA 2001 785 795
2. A.P. Armstrong, M.E. Tometsko, M. Glaccum, C.L. Sutherland, D. Cosman, and W.C. Dougall A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function J. Biol. Chem. 277 2002 44347 44356
3. B.F. Boyce, and L. Xing The RANKL/RANK/OPG pathway Curr. Osteoporos. Rep. 5 2007 98 104
4. B.G. Darnay, and B.B. Aggarwal Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors Ann. Rheum. Dis. 58 1999 I2 I13
5. B.G. Darnay, A. Besse, A.T. Poblenz, B. Lamothe, and J.J. Jacoby TRAFs in RANK signaling Adv. Exp. Med. Biol. 597 2007 152 159
6. C. Delgado, R.B. Pedley, A. Herraez, R. Boden, J.A. Boden, P.A. Keep, K.A. Chester, D. Fisher, R.H. Begent, and G.E. Francis Enhanced tumour specificity of an anti-carcinoembryonic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification Br. J. Cancer 73 1996 175 182
7. E.A. Eno-Amooquaye, F. Searle, J.A. Boden, S.K. Sharma, and P.J. Burke Altered biodistribution of an antibody-enzyme conjugate modified with polyethylene glycol Br. J. Cancer 73 1996 1323 1327
8. U. Gaur, S.K. Sahoo, T.K. De, P.C. Ghosh, A. Maitra, and P.K. Ghosh Biodistribution of fluorescinated dextran using novel nanoparticles evading reticuloendothelial system Int. J. Pharm. 202 2000 1 10
9. D.E. Hughes, A. Dai, J.C. Tiffee, H.H. Li, G.R. Mundy, and B.F. Boyce Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta Nat. Med. 2 1996 1132 1136
10. R.L. Jilka, G. Hangoc, G. Girasole, G. Passeri, D.C. Williams, J.S. Abrams, B. Boyce, H. Broxmeyer, and S.C. Manolagas Increased osteoclast development after estrogen loss: mediation by interleukin-6 Science 257 1992 88 91
11. N.V. Katre, M.J. Knauf, and W.J. Laird Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model Proc. Natl. Acad. Sci. U.S.A. 84 1987 1487 1491
12. S. Khosla Minireview: the OPG/RANKL/RANK system Endocrinology 142 2001 5050 5055
13. M.M. Kurfurst Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis Anal. Biochem. 200 1992 244 248
14. S. Lien, and H.B. Lowman Therapeutic peptides Trends Biotechnol. 21 2003 556 562
15. M.A. Lomaga, W.C. Yeh, I. Sarosi, G.S. Duncan, C. Furlonger, A. Ho, S. Morony, C. Capparelli, G. Van, S. Kaufman, A. van der Heiden, A. Itie, A. Wakeham, W. Khoo, T. Sasaki, Z. Cao, J.M. Penninger, C.J. Paige, D.L. Lacey, C.R. Dunstan, W.J. Boyle, D.V. Goeddel, and T.W. Mak TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling Genes Dev. 13 1999 1015 1024
16. H. Maeda, L.W. Seymour, and Y. Miyamoto Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo Bioconjug. Chem. 3 1992 351 362
17. M. McClung Role of RANKL inhibition in osteoporosis Arthritis Res. Ther. 9 2007 S3
18. S. Parveen, and S.K. Sahoo Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs Clin. Pharmacokinet. 45 2006 965 988
19. A.T. Poblenz, J.J. Jacoby, S. Singh, and B.G. Darnay Inhibition of RANKL-mediated osteoclast differentiation by selective TRAF6 decoy peptides Biochem. Biophys. Res. Commun. 359 2007 510 515
20. A.K. Sato, M. Viswanathan, R.B. Kent, and C.R. Wood Therapeutic peptides: technological advances driving peptides into development Curr. Opin. Biotechnol. 17 2006 638 642
21. W.S. Simonet, D.L. Lacey, C.R. Dunstan, M. Kelley, M.S. Chang, R. Luthy, H.Q. Nguyen, S. Wooden, L. Bennett, T. Boone, G. Shimamoto, M. DeRose, R. Elliott, A. Colombero, H.L. Tan, G. Trail, J. Sullivan, E. Davy, N. Bucay, L. Renshaw-Gegg, T.M. Hughes, D. Hill, W. Pattison, P. Campbell, S. Sander, G. Van, J. Tarpley, P. Derby, R. Lee, and W.J. Boyle Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 1997 309 319
22. M. Terauchi, H. Kajiyama, K. Shibata, K. Ino, A. Nawa, S. Mizutani, and F. Kikkawa Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells BMC Cancer 7 2007 140
23. F.M. Veronese PEGylated Protein Drugs: Basic Science and Clinical Applications 2009 Birkhäuser Basel
24. F.M. Veronese Peptide and protein PEGylation: a review of problems and solutions Biomaterials 22 2001 405 417
25. F.M. Veronese, and M. Morpurgo Bioconjugation in pharmaceutical chemistry Farmaco 54 1999 497 516
26. F.M. Veronese, and G. Pasut PEGylation, successful approach to drug delivery Drug Discov. Today 10 2005 1451 1458
27. P. Vlieghe, V. Lisowski, J. Martinez, and M. Khrestchatisky Synthetic therapeutic peptides: science and market Drug Discov. Today 15 2010 40 56
28. R.S. Weinstein, R.L. Jilka, A.M. Parfitt, and S.C. Manolagas The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage Endocrinology 138 1997 4013 4021
29. M. Werle, and A. Bernkop-Schnurch Strategies to improve plasma half life time of peptide and protein drugs Amino Acids 30 2006 351 367
30. H. Ye, J.R. Arron, B. Lamothe, M. Cirilli, T. Kobayashi, N.K. Shevde, D. Segal, O.K. Dzivenu, M. Vologodskaia, M. Yim, K. Du, S. Singh, J.W. Pike, B.G. Darnay, Y. Choi, and H. Wu Distinct molecular mechanism for initiating TRAF6 signalling Nature 418 2002 443 447